---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-007478"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:12:57.800615+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PDS Biotechnology receives Nasdaq bid price deficiency notice; 180 days to cure

## Summary
- Stock closed below $1.00 for 30 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.
- Company has 180 calendar days, until August 24, 2026, to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not compliant by deadline, company may seek a second 180-day period if it meets other listing standards.
- Potential remedies include a reverse stock split; delisting could occur if compliance is not achieved.
- Common stock continues trading on Nasdaq under symbol PDSB with no immediate impact.

## SEC filing metadata
- accession: 0001140361-26-007478
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036126007478/0001140361-26-007478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036126007478/ef20067044_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-007478
- JSON: https://secwatch.observer/filing/0001140361-26-007478.json
- Plain text: https://secwatch.observer/filing/0001140361-26-007478.txt

## Source-grounded claims
- claim_id: 610e86525854bfe62f98f0f17f72f30e9c8a5190
  claim: PDS Biotechnology Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  evidence_excerpt: February 25, 2026, PDS Biotechnology Corporation (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s comm
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036126007478/0001140361-26-007478-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.